MedPath
HSA Approval

UBIT® Tablet 100 mg

SIN13253P

UBIT® Tablet 100 mg

UBIT® Tablet 100 mg

April 19, 2007

NAGASE SINGAPORE (PTE) LTD

NAGASE SINGAPORE (PTE) LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantNAGASE SINGAPORE (PTE) LTD
Licence HolderNAGASE SINGAPORE (PTE) LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET

**DOSAGE AND ADMINISTRATION** Usual adult dosage is one tablet \[100 mg of urea (13C)\] taken orally in a fasting condition. < **Recommended Procedure for 13C-Urea Breath Test** > 1. Collect pre-dose breath sample. 2. Instruct patient in a fasting condition to promptly (within 5 sec) swallow one tablet of UBIT Tablet 100mg with 100 mL of water without crushing or chewing the tablet. 3. Instruct patient to remain in left lateral decubitus position for 5 min, and then to return to sitting position until collection of post-dose breath sample. 4. Collect post-dose breath sample at 20 min after administration. 5. Measure 13CO2 level (ratio of 13CO2 to 12CO2) in each breath sample and calculate Δ13CO2 (difference between pre-dose and post-dose 13CO2 levels) for diagnosis of _H. pylori_ infection.

ORAL

Medical Information

**INDICATIONS** _In vivo_ diagnosis of _Helicobacter pylori_ ( _H. pylori_) infection

**5\. Contraindications** Hypersensitivity to active substance or to any of the excipients.

Manufacturer Information

NAGASE SINGAPORE (PTE) LTD.

Tokushima Factory, Otsuka Pharmaceutical Co., Ltd

Active Ingredients

13C UREA

100mg

Urea C-13

Documents

Package Inserts

UBIT Tablet PI.pdf

Approved: September 10, 2020

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

UBIT® Tablet 100 mg - HSA Approval | MedPath